A crisis reopened by tragedy
The death of actress Hayden Panettiere on Aug. 16, at age 36, has reopened one of the more uncomfortable episodes in celebrity endorsement and left Neutrogena facing a reputational crisis it has done almost nothing to address. Panettiere, who rose to fame on NBC’s Heroes, was found unresponsive at a residence in Greenville, South Carolina, in what has been reported as a suspected overdose. Within hours, clips resurfaced of the actress alleging that Neutrogena had moved to end its relationship with her after she spoke publicly about postpartum depression in 2015.
The claim, made during the promotion of her memoir This Is Me: A Reckoning, published by Hachette in May, and in an interview on Jay Shetty’s On Purpose podcast, had circulated once before. Her death gave it a moral weight it did not carry the first time, and the response online has been swift and punishing.
What happened in 2015
Panettiere’s account traces to a September 2015 appearance on Live! With Kelly and Michael, less than a year after the birth of her daughter, when she spoke candidly about her experience with postpartum depression. By her telling, word reached her almost immediately that Neutrogena, a brand she had worked with for roughly a decade, wanted to invoke a morals clause and terminate her contract. Her representatives argued that firing someone over a medical condition was unlawful, and the brand stepped back. She finished the remaining term of the agreement, but it was not renewed.
Neutrogena has never publicly confirmed or contested that version of events. It did not respond when the allegations first surfaced during the book’s release, and it has not responded since her death.
Why it detonated now
The reaction has moved at the speed of social platforms. A Reddit thread calling for a boycott passed 5,000 upvotes, a post on X carrying the same message drew more than 39,000 likes and over a million views, and TMZ reported the brand had been flooded with hate mail. Neutrogena’s parent, Kenvue, the consumer-health company that also owns Tylenol, Band-Aid and Aveeno, saw its shares close about 2% lower on Aug. 17, though that move cannot be attributed to the controversy alone.
The intensity is a function of the story’s ingredients. It joins a beloved public figure, an early and sympathetic disclosure of mental illness, a decade-old corporate decision that now reads as punitive, and a tragic death that leaves the whole sequence feeling unresolved. That combination is combustible in a way a routine endorsement dispute is not.
The cost of saying nothing
Crisis communication offers a familiar principle: silence is itself a message, and in a vacuum audiences write the worst version of the story. A no-comment posture can be defensible when the facts are contested or litigation looms. It becomes corrosive when the accusation is morally charged, the accuser can no longer speak, and the public has already reached a verdict. Adweek’s Robert Klara argued that it may be too late for Neutrogena to repair the damage, and the logic is hard to dismiss. Every day without a humane, human response lets the narrative harden.
The difficulty for Kenvue is real. Any statement risks looking defensive, opportunistic or legally fraught, and a clumsy one could pour fuel on the fire. But the absence of even an expression of sympathy, or an acknowledgment of how seriously the company now treats maternal mental health, reads to many as indifference. In reputation terms, indifference is the most expensive posture of all.
What brands should take from it
The episode is a lesson in how the past does not stay past. Any endorsement decision, however old, can be exhumed and re-judged by standards that have shifted, and mental health is precisely the terrain where public expectations have moved fastest. Brands that publicly champion wellbeing will be measured against how they treated it when it was inconvenient, and morals clauses drafted for scandal can look indefensible when applied to illness.
The practical takeaways are not complicated. Audit the commitments the brand makes today against the decisions in its archive. Prepare for the reality that a company’s values will be tested against its history, not just its campaigns. And recognize that when a crisis carries real human grief, the first requirement is not legal caution or message discipline but visible humanity. Neutrogena’s continuing silence suggests that lesson is still being learned the hard way.
